AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3503570 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 10
Study 3503570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31986170 — intervention group
Group type: EXPERIMENTAL
Intervention: NAXOZOL (naproxen 500 mg, esomeprazole strontium tetrahydrate 20 mg) twice per day
Number of subjects: 0
Study 31986170 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg daily
Number of subjects: 0
Study 31986170 — intervention group
Group type: EXPERIMENTAL
Intervention: NAXOZOL
Number of subjects: 0
Study 31986170 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 0
Study 31986170 — intervention group
Group type: EXPERIMENTAL
Intervention: NAXOZOL and Celecoxib
Number of subjects: 0
Study 29767350 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet only
Number of subjects: 124
Study 29767350 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and aerobic exercise training
Number of subjects: 124
Study 29767350 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and resistance exercise training
Number of subjects: 124
Study 26338825 — intervention group
Group type: EXPERIMENTAL
Intervention: S10 (sequential therapy for 10 days)
Number of subjects: 1300
Study 26338825 — intervention group
Group type: COMPARATOR
Intervention: T14 (triple therapy for 14 days)
Number of subjects: 1300
Study 26338825 — intervention group
Group type: EXPERIMENTAL
Intervention: S10
Number of subjects: 1300
Study 26338825 — intervention group
Group type: COMPARATOR
Intervention: T14
Number of subjects: 1300
Study 24373984 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP + FACT (n=39)
Number of subjects: 79
Study 24373984 — intervention group
Group type: COMPARATOR
Intervention: iCBT (n=40)
Number of subjects: 79
Study 24373984 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=39)
Number of subjects: 79
Study 24373984 — intervention group
Group type: COMPARATOR
Intervention: AMP (active condition reported by Carlbring et al.)
Number of subjects: 79
Study 22932084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefarnate 300 mg daily for six weeks
Number of subjects: 253
Study 22932084 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate 3 g daily for six weeks
Number of subjects: 253
Study 20219096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led intervention plus education pack
Number of subjects: 121
Study 20219096 — intervention group
Group type: COMPARATOR
Intervention: Education pack only
Number of subjects: 121
Study 16778147 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum plus motivational interviewing (MI)
Number of subjects: 173
Study 16778147 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing (MI) and educational materials addressing fruit and vegetable consumption
Number of subjects: 173
Study 15703500 — intervention group
Group type: EXPERIMENTAL
Intervention: Qi Gong and group discussions
Number of subjects: 95
Study 15703500 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 95
Study 12074370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavior therapy (CBT)
Number of subjects: 0
Study 12074370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CBT+PCT (COMB)
Number of subjects: 0
Study 12074370 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy (PCT)
Number of subjects: 0
Study 12074370 — intervention group
Group type: COMPARATOR
Intervention: Medication placebo (PLA)
Number of subjects: 0
Study 9788025 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotrolan 320
Number of subjects: 120
Study 9788025 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 350
Number of subjects: 120
Study 8109654 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of trihexyphenidyl twice daily for 4 weeks
Number of subjects: 17
Study 8109654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2669445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 47
Study 2669445 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 47
Study 775358 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg LHRH nasal spray per day
Number of subjects: 20
Study 775358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30569507 — intervention group
Group type: EXPERIMENTAL
Intervention: LCR1 and LCR2 tests
Number of subjects: 9892
Study 30569507 — intervention group
Group type: COMPARATOR
Intervention: Standard surveillance (imaging with or without AFP)
Number of subjects: 9892
Study 27712095 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐Determination Theory (SDT) intervention designed to promote oral health care competence in an autonomy‐supportive way
Number of subjects: 138
Study 27712095 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 138
Study 26700738 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (EPO)
Number of subjects: 227
Study 26700738 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPO)
Number of subjects: 227
Study 26700738 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 227
Study 25273991 — intervention group
Group type: EXPERIMENTAL
Intervention: CBPT Program
Number of subjects: 260
Study 25273991 — intervention group
Group type: COMPARATOR
Intervention: Education Program
Number of subjects: 260
Study 22428137 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg per day oral supplementation and 2 ml (78.9 μM solution) per day topical application of astaxanthin (open-label non-controlled study)
Number of subjects: 66
Study 22428137 — intervention group
Group type: COMPARATOR
Intervention: 6 mg of astaxanthin daily supplementation (randomized double-blind placebo controlled study)
Number of subjects: 66
Study 20134279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, one-on-one educational intervention
Number of subjects: 20
Study 18030651 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (BZDs) prescribed
Number of subjects: 505
Study 18030651 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (BZDs) use
Number of subjects: 505
Study 18030651 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple logistic regression analysis
Number of subjects: 505
Study 15630360 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaifenesin
Number of subjects: 54
Study 15630360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 15630360 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+ group
Number of subjects: 54
Study 12083347 — intervention group
Group type: EXPERIMENTAL
Intervention: lavender vera (lavendula officinalis)
Number of subjects: 13
Study 12083347 — intervention group
Group type: EXPERIMENTAL
Intervention: sweet orange (citrus aurantium)
Number of subjects: 13
Study 12083347 — intervention group
Group type: EXPERIMENTAL
Intervention: tea tree (malaleuca alternifolia)
Number of subjects: 13
Study 12083347 — intervention group
Group type: COMPARATOR
Intervention: no aroma (control)
Number of subjects: 13
Study 10466845 — intervention group
Group type: EXPERIMENTAL
Intervention: BULIT test with long term clinical treatment strategy
Number of subjects: 0
Study 10466845 — intervention group
Group type: COMPARATOR
Intervention: BULIT test
Number of subjects: 0
Study 8830062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (200 mg) administered twice daily from the evening of day 2 to the morning of day 9, with triazolam (0.25 mg) on days 8 and 9.
Number of subjects: 12
Study 8830062 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered on days 1 and 2, with triazolam (0.25 mg) on days 8 and 9.
Number of subjects: 12
Study 1512434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring to promote adaptive beliefs about memory
Number of subjects: 5
Study 1512434 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory skills training
Number of subjects: 5
Study 1512434 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive restructuring and memory skills training
Number of subjects: 5
Study 1512434 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice on memory tasks
Number of subjects: 5
Study 1512434 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 5
Study 6235779 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicodendron antigen patch test
Number of subjects: 0
Study 6235779 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed (96-hour) patch test reading
Number of subjects: 0
Study 30284455 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite sinus stent implantation for 14 to 28 days
Number of subjects: 30
Study 30284455 — intervention group
Group type: COMPARATOR
Intervention: Telfa tampon placement for 2 to 3 days
Number of subjects: 30
Study 29282354 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic bag intervention
Number of subjects: 108
Study 29282354 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 108
Study 26799942 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (6 grams per day for 3 months)
Number of subjects: 39
Study 26799942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 28526087 — intervention group
Group type: EXPERIMENTAL
Intervention: New Opportunities (DNK)
Number of subjects: 300
Study 28526087 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 300
Study 23400604 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 850
Study 23400604 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron/folic acid (60 mg iron)
Number of subjects: 850
Study 23400604 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (30 mg iron)
Number of subjects: 850
Study 23400604 — intervention group
Group type: COMPARATOR
Intervention: Control group (prenatal-non-IDA)
Number of subjects: 850
Study 20878213 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace fitness program (3 sessions per week for 8 months, 15 minutes per session, focusing on stretching exercises)
Number of subjects: 50
Study 20878213 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 19950567 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride
Number of subjects: 48
Study 19950567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cresol
Number of subjects: 48
Study 19950567 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 48
Study 17171354 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidopexy (SH)
Number of subjects: 596
Study 17171354 — intervention group
Group type: COMPARATOR
Intervention: Ferguson hemorrhoidectomy (FH)
Number of subjects: 596
Study 15238825 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 40
Study 11220045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 18
Study 11220045 — intervention group
Group type: COMPARATOR
Intervention: Controls (no medication)
Number of subjects: 18
Study 11220045 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pill users with controls
Number of subjects: 18
Study 11220045 — intervention group
Group type: COMPARATOR
Intervention: Normal cyclic variations in healthy young females
Number of subjects: 18
Study 9627608 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine iontophoresis
Number of subjects: 42
Study 9627608 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 42
Study 7604686 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pudendal nerve terminal motor latencies > 2.0 milliseconds
Number of subjects: 113
Study 7604686 — intervention group
Group type: COMPARATOR
Intervention: Patients and controls (3 months post partum)
Number of subjects: 113
Study 7604686 — intervention group
Group type: COMPARATOR
Intervention: Incontinent patients and continent patients
Number of subjects: 113
Study 7604686 — intervention group
Group type: COMPARATOR
Intervention: Control women
Number of subjects: 113
Study 2194899 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat probe coagulation (30 patients)
Number of subjects: 61
Study 2194899 — intervention group
Group type: COMPARATOR
Intervention: Observation alone (31 patients)
Number of subjects: 61
Study 372565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intercostal nerve block with bupivacaine
Number of subjects: 30
Study 372565 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 30926995 — intervention group
Group type: EXPERIMENTAL
Intervention: Debiasing intervention (visual aid and explanatory text)
Number of subjects: 311
Study 30926995 — intervention group
Group type: COMPARATOR
Intervention: Control stimulus
Number of subjects: 311
Study 30926995 — intervention group
Group type: COMPARATOR
Intervention: Post-test only group
Number of subjects: 311
Study 30777495 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed ovarian tissue at 0 min
Number of subjects: 11
Study 30777495 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed ovarian tissue at 20 min
Number of subjects: 11
Study 30777495 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed ovarian tissue at 40 min
Number of subjects: 11
Study 30777495 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed ovarian tissue at 60 min
Number of subjects: 11
Study 30777495 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed ovarian tissue at 80 min
Number of subjects: 11
Study 30777495 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed ovarian tissue at 100 min
Number of subjects: 11
Study 30777495 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed ovarian tissue at 120 min
Number of subjects: 11
Study 28860419 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps cooling (QC)
Number of subjects: 30
Study 28860419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring cooling (HC)
Number of subjects: 30
Study 28860419 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cooling)
Number of subjects: 30
Study 26193339 — intervention group
Group type: EXPERIMENTAL
Intervention: High DNA index (>1.4)
Number of subjects: 143
Study 26193339 — intervention group
Group type: COMPARATOR
Intervention: Low DNA index (G1/2 tumor grading)
Number of subjects: 143
Study 26193339 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA index and tumor grading
Number of subjects: 143
Study 26193339 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic subgroups based on DNA index and tumor grading
Number of subjects: 143
Study 23263865 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 1684
Study 23263865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil + Belimumab
Number of subjects: 1684
Study 23263865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1684
Study 20855467 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA‐paclitaxel at a starting dose of 900 mg/m(2) IV on day 1 every 3 weeks
Number of subjects: 393
Study 20855467 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine at a starting dose of 1000 mg/m(2) IV on day 1 every 3 weeks
Number of subjects: 393
Study 20855467 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA‐paclitaxel
Number of subjects: 393
Study 20855467 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 393
Study 19576297 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal enemas (3 enemas/week, reduced by 1 enema/week every 3 months)
Number of subjects: 100
Study 19576297 — intervention group
Group type: COMPARATOR
Intervention: Oral laxatives (control group)
Number of subjects: 100
Study 19576297 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 100
Study 17101006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair dye A (24 hr exposure)
Number of subjects: 3
Study 17101006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair dye B (24 hr exposure)
Number of subjects: 3
Study 17101006 — intervention group
Group type: COMPARATOR
Intervention: 1% PPD/petrolatum (48 hr exposure)
Number of subjects: 3
Study 14985212 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpea-based meal
Number of subjects: 20
Study 14985212 — intervention group
Group type: COMPARATOR
Intervention: Wheat-based meal
Number of subjects: 20
Study 14985212 — intervention group
Group type: COMPARATOR
Intervention: White bread meal
Number of subjects: 20
Study 11710999 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MIU IFN-alpha s.c. daily for 32 consecutive days (IFN-alphaT group)
Number of subjects: 27
Study 11710999 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (IFN-alphaNT group)
Number of subjects: 27
Study 9135948 — intervention group
Group type: EXPERIMENTAL
Intervention: sulodexide (100 mg/day)
Number of subjects: 12
Study 9135948 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 7957000 — intervention group
Group type: EXPERIMENTAL
Intervention: Codfish (1 g fat, 23 g protein per 100 g)
Number of subjects: 7
Study 7957000 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnuts (64 g fat, 7 g protein, 15 g starch per 100 g)
Number of subjects: 7
Study 7957000 — intervention group
Group type: COMPARATOR
Intervention: Bananas (22 g starch, 1 g protein per 100 g)
Number of subjects: 7
Study 2193498 — intervention group
Group type: EXPERIMENTAL
Intervention: Indecainide
Number of subjects: 32
Study 2193498 — intervention group
Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 32
Study 380579 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine
Number of subjects: 0
Study 380579 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 31144466 — intervention group
Group type: EXPERIMENTAL
Intervention: Test in Mandarin developed from the Claim Evaluation Tools database, consisting of 21 MCQs after deletion of 3 with suboptimal fit.
Number of subjects: 389
Study 29143634 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 3 μg/kg of moxidectin
Number of subjects: 9
Study 29143634 — intervention group
Group type: EXPERIMENTAL
Intervention: Three consecutive monthly doses of 3 μg/kg of moxidectin
Number of subjects: 9
Study 25888086 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ Care System
Number of subjects: 130
Study 25888086 — intervention group
Group type: COMPARATOR
Intervention: Standard cold storage
Number of subjects: 130
Study 23475780 — intervention group
Group type: EXPERIMENTAL
Intervention: Net fluid loss in the first 24 hours
Number of subjects: 475
Study 23475780 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline right atrial pressure (RAP) and decrease in RAP
Number of subjects: 475
Study 21447866 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetectable viraemia at week 24
Number of subjects: 871
Study 21447866 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable viraemia <15 IU/ml at week 24
Number of subjects: 871
Study 21447866 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable viraemia 15-<50 IU/ml at week 24
Number of subjects: 871
Study 21447866 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative predictive value (NPV) for SVR using TaqMan cutoffs
Number of subjects: 871
Study 21447866 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between Amplicor and TaqMan assays
Number of subjects: 871
Study 19905037 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART programme
Number of subjects: 1045
Study 17112296 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson (CVT‐3146) at doses ranging from 0.1 to 30.0 micro g/kg
Number of subjects: 36
Study 17112296 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson (CVT‐3146)
Number of subjects: 36
Study 17112296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16212202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single dose)
Number of subjects: 200
Study 16212202 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin/cloxacillin (3 doses)
Number of subjects: 200
Study 11327628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg, p.o.)
Number of subjects: 64
Study 11327628 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg, p.o.)
Number of subjects: 64
Study 11327628 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (normotensive subjects)
Number of subjects: 64
Study 9394872 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex (DIVAL)
Number of subjects: 176
Study 9394872 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (LI)
Number of subjects: 176
Study 9394872 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 176
Study 7906406 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane-diethyl ether azeotrope anesthesia (HE)
Number of subjects: 20
Study 7906406 — intervention group
Group type: COMPARATOR
Intervention: Halothane/nitrous oxide anesthesia
Number of subjects: 20
Study 3821177 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (975 mg three times daily)
Number of subjects: 68
Study 3821177 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and ethanol (maximal doses for 3 days)
Number of subjects: 68
Study 3821177 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (300 ml of 5% or 30 ml of 50% three times nightly)
Number of subjects: 68
Study 28005616 — intervention group
Group type: EXPERIMENTAL
Intervention: TDR
Number of subjects: 229
Study 28005616 — intervention group
Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 229
Study 27798345 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified orange maize (OM) - 2 meals/d, 6 d/wk for 6 mo
Number of subjects: 1024
Study 27798345 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified orange maize (OM)
Number of subjects: 1024
Study 27798345 — intervention group
Group type: COMPARATOR
Intervention: White maize (WM) - 2 meals/d, 6 d/wk for 6 mo
Number of subjects: 1024
Study 25543421 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of acupuncture and auricular acupressure
Number of subjects: 60
Study 25543421 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine hydrochloride capsules (20 mg, once a day)
Number of subjects: 60
Study 24045520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic trabeculoplasty (PNT) plus latanoprost
Number of subjects: 30